Back to Search
Start Over
Sipuleucel-T: immunotherapy for advanced prostate cancer
- Source :
- Open Access Journal of Urology, Vol 2011, Iss default, Pp 49-60 (2011)
- Publication Year :
- 2011
- Publisher :
- Dove Medical Press, 2011.
-
Abstract
- Brian M Olson, Douglas G McNeelUniversity of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison, Madison, WI, USAAbstract: Prostate cancer continues to be one of the most serious afflictions of men of advanced age, remaining the most commonly diagnosed and second leading cause of cancer-related deaths in American men. The treatment options for patients with incurable metastatic, castrate-resistant disease have long focused on various chemotherapeutic approaches, which provide a slight survival benefit while being associated with potentially significant side effects. However, the recent approval of sipuleucel-T has given patients with advanced disease an additional treatment option that has demonstrated benefit without the side effects associated with chemotherapy. Sipuleucel-T is an antigen-presenting cell-based active immunotherapy that utilizes a patient's own immune cells, presumably to activate an antigen-specific immune response against tumor cells. This review focuses on the development and implementation of sipuleucel-T as a therapy for prostate cancer. Specifically, we present some of the issues associated with the management of advanced prostate cancer, the research and development that led to the approval of sipuleucel-T, how the approval of sipuleucel-T could change the clinical management of prostate cancer, and current and future areas of investigation that are being pursued with regard to sipuleucel-T and other treatments for advanced prostate cancer.Keywords: sipuleucel-T, prostatic acid phosphatase, granulocyte-macrophage colonystimulating factor
Details
- Language :
- English
- ISSN :
- 11791551
- Volume :
- 2011
- Database :
- OpenAIRE
- Journal :
- Open Access Journal of Urology
- Accession number :
- edsair.doajarticles..c30828b873bd624c332cf2bb07c9cff4